



Canadian  
Cancer Clinical  
Trials Network

Réseau canadien  
d'essais cliniques  
sur le cancer

Canadian Cancer Clinical Trials Network

# 3CTN Y10Q1 Performance Report

April 1, 2023 – June 30, 2023


## Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials .....	2
Patient Recruitment at All Network Sites .....	2
Patient Access: Adolescent and Young Adult (AYA) and Remote Access Recruitment .....	3
Portfolio Trials and Accruals by Region/Site .....	4
Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Alberta, British Columbia, and Manitoba .....	4
Number of active recruiting 3CTN Portfolio trials – Alberta, British Columbia, and Manitoba .....	5
Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Ontario .....	6
Number of active recruiting 3CTN Portfolio trials – Ontario .....	7
Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Newfoundland and Quebec.....	8
Number of active recruiting 3CTN Portfolio Trials – Newfoundland and Quebec.....	9
Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Pediatric Cancer Centres.....	10
Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres .....	11
Section B: 3CTN Portfolio Metrics.....	12
Active Recruiting Portfolio Trials by Disease Site and Phase .....	12
Overview of Portfolio Applications – Process Efficiency.....	13
Trials Added to the 3CTN Portfolio in Y10Q1 (April 1 – June 30, 2023).....	14

# Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

## Patient Recruitment at All Network Sites

**Objective:** To improve patient access to academic clinical trials and improve patient recruitment by greater than 100% within five years.



### Notes:

- 990 patients were recruited (954 to Adult and 36 to Pediatric cancer centres) to Portfolio trials in Quarter 1.
- Overall, ~24% of Adult Sites (9 out of 38) are on track to reach their Y10 target.
- \*Pediatric progress to pre-3CTN baseline recruitment is shown. At the end of Q1, 23% of Pediatric sites (3 out of 13) are on track to reach their pre-3CTN baseline in Y10.

## Patient Access: Adolescent and Young Adult (AYA) and Remote Access Recruitment

**Objective:** To improve trial access and overcome barriers to trial participation for under-represented populations.

Network Site	Primary Site Remote Access Patient*	Satellite Site Remote Access Patient	AYA Accrual (Aged 15-39)
CancerCare Manitoba	1		
Centre hospitalier universitaire de Sainte-Justine			2
Children's Hospital - London Health Sciences Centre	1		1
Children's Hospital of Eastern Ontario	2		1
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	2		1
Humber River Hospital	2		
IWK Health Centre	1		3
Jim Pattison Children's Hospital			1
Sunnybrook Health Sciences Centre	1		
The Hospital for Sick Children			1
Walker Family Cancer Centre			1
<b>Total</b>	<b>10</b>	<b>0</b>	<b>11</b>

\*Table excludes remote access patients recruited through the Canadian Remote Access Framework for Clinical Trials (CRAFT) proof of concept project. Numbers based on date of remote access initiation.

## Portfolio Trials and Accruals by Region/Site

Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Alberta, British Columbia, and Manitoba

Network Site	Pre-3CTN Baseline	Y5 Total	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10		
							Q1	% of Baseline	% of Target
CancerCare Manitoba	99	98	51	44	59	90	22	22%	12%
Western Manitoba Cancer Centre	1	1	1	0	1	4	1	100%	54%
<b>Manitoba Total</b>	<b>100</b>	<b>99</b>	<b>51</b>	<b>44</b>	<b>60</b>	<b>94</b>	<b>23</b>	<b>23%</b>	<b>12%</b>
BC Cancer – Vancouver	106	107	110	154	175	203	40	38%	20%
BC Cancer – Abbotsford	16	22	1	1	2	8	1	6%	3%
BC Cancer – Prince George	1	9	10	14	21	13	2	200%	108%
BC Cancer – Kelowna	38	38	33	36	35	56	20	53%	28%
BC Cancer – Victoria	26	69	78	40	42	35	8	31%	17%
BC Cancer – Surrey	44	-	-	-	-	21	14	32%	17%
<b>British Columbia Total</b>	<b>231</b>	<b>245</b>	<b>232</b>	<b>245</b>	<b>275</b>	<b>336</b>	<b>85</b>	<b>37%</b>	<b>20%</b>
Tom Baker Cancer Centre	76	139	341	248	166	-	15	20%	11%
<b>Alberta Total</b>	<b>76</b>	<b>242</b>	<b>651</b>	<b>450</b>	<b>284</b>	<b>-</b>	<b>15</b>	<b>20%</b>	<b>11%</b>
<b>Western Region Total</b>	<b>407</b>	<b>586</b>	<b>934</b>	<b>739</b>	<b>619</b>	<b>430</b>	<b>123</b>	<b>30%</b>	<b>16%</b>

Number of active recruiting 3CTN Portfolio trials – Alberta, British Columbia, and Manitoba

Network Site	Pre-3CTN Baseline	Y6 (2019-20)				Y7 (2020-21)				Y8 (2021-22)				Y9 (2022-23)				Y10 (2023-24)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
CancerCare Manitoba	37	22	19	16	22	13	20	18	17	17	17	15	15	17	17	16	17	19
Western Manitoba Cancer Centre	0	1	1	1	1	1	1	1	1	1	1	2	2	2	2	2	2	2
BC Cancer – Vancouver	50	26	25	23	27	16	17	19	28	29	27	29	30	31	40	40	43	44
BC Cancer – Abbotsford	6	5	5	0	0	1	1	0	0	0	1	1	2	2	3	2	2	2
BC Cancer – Prince George	2	2	2	3	3	4	5	4	6	6	5	5	8	3	4	5	5	5
BC Cancer – Kelowna	23	5	5	5	7	4	5	5	5	8	8	8	4	10	10	10	11	11
BC Cancer – Victoria	12	8	7	6	6	7	9	7	10	11	8	9	10	11	9	9	9	13
BC Cancer – Surrey	6	-	-	-	-	-	-	-	-	-	-	-	-	7	7	7	7	7
Tom Baker Cancer Centre	20	30	34	33	33	28	28	23	25	23	25	25	22	-	-	-	-	29

Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Ontario

Network Site	Pre-3CTN Baseline	Y5 Total	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10		
							Q1	% of Baseline	% of Target
London Health Sciences Centre	186	248	942	693	656	506	259	139%	75%
Grand River Regional Cancer Centre	20	34	19	24	23	58	8	40%	22%
Windsor Regional Cancer Centre	14	16	3	2	3	2	1	7%	4%
Juravinski Cancer Centre	181	345	217	142	190	136	42	23%	13%
Cambridge Memorial Hospital	11	5	8	9	11	6	0	0%	0%
St. Joseph's Healthcare Hamilton	21	40	20	54	87	56	0	0%	0%
Walker Family Cancer Centre	17	37	40	7	23	38	4	24%	13%
Oakville Trafalgar Memorial Hospital	1	-	-	-	-	0	0	0%	0%
Sunnybrook Health Sciences Centre	141	651	638	395	671	593	143	101%	55%
Humber River Health	1	7	3	4	2	14	11	1100%	595%
Michael Garron Hospital	2	2	0	0	0	0	0	0%	0%
Princess Margaret Cancer Centre	396	720	543	267	338	390	136	34%	19%
Markham Stouffville Hospital	1	2	6	3	0	6	0	0%	0%
Mount Sinai Hospital	21	12	7	67	543	121	1	5%	3%
Northeast Cancer Centre	24	18	17	7	2	5	1	4%	2%
North York General Hospital	1	9	7	7	10	21	2	200%	108%
Royal Victoria Regional Health Centre	8	9	25	13	44	37	7	88%	47%
St. Michael's Hospital	19	1	3	0	9	1	0	0%	0%
Southlake Regional Health Centre	10	68	32	9	13	9	0	0%	0%
Thunder Bay Regional Health Sciences Centre	26	25	4	2	39	22	0	0%	0%
Trillium Health Partners - Credit Valley Hospital	27	12	10	2	10	12	0	0%	0%
William Osler Health System	1	0	16	2	3	6	0	0%	0%
The Ottawa Hospital Cancer Centre	132	850	804	483	771	830	147	111%	60%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	72	89	59	52	48	10	24%	13%
R.S. McLaughlin Durham Regional Cancer Centre	22	15	36	3	7	26	4	18%	10%
<b>Central Region Total</b>	<b>1324</b>	<b>3198</b>	<b>3489</b>	<b>2254</b>	<b>3507</b>	<b>2943</b>	<b>776</b>	<b>59%</b>	<b>32%</b>

## Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y6 (2019-20)				Y7 (2020-21)				Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
London Health Sciences Centre	79	47	52	54	57	45	47	44	41	42	38	39	36	32	29	31	29	30
Grand River Regional Cancer Centre	11	6	7	8	8	8	8	8	8	6	7	7	8	11	11	11	11	10
Windsor Regional Cancer Centre	4	4	4	4	3	4	2	2	2	2	2	2	2	8	3	3	3	3
Juravinski Cancer Centre	51	22	26	24	34	13	31	34	35	38	31	35	37	36	29	27	27	36
Cambridge Memorial Hospital	5	2	2	2	2	2	2	2	2	2	3	3	2	2	2	2	2	2
St. Joseph's Healthcare Hamilton	2	1	1	1	1	1	1	2	2	2	2	2	2	2	2	2	2	2
Walker Family Cancer Centre	10	6	6	8	7	8	7	7	7	6	6	6	8	8	8	8	7	7
Oakville Trafalgar Memorial Hospital		-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Sunnybrook Health Sciences Centre	10	34	36	36	35	47	35	34	33	32	30	35	40	45	48	48	53	50
Humber River Health	0	2	2	3	2	3	2	1	1	1	0	2	1	0	1	1	1	1
Michael Garron Hospital	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0
Princess Margaret Cancer Centre	91	78	88	89	80	80	81	82	65	68	68	66	64	73	74	74	75	81
Markham Stouffville Hospital	0	1	0	1	1	1	1	1	1	0	0	1	1	2	2	2	2	1
Mount Sinai Hospital	6	4	5	6	3	3	2	2	3	3	2	3	3	3	3	3	4	4
Northeast Cancer Centre	10	7	7	7	7	8	7	7	8	9	9	9	9	9	9	9	11	10
North York General Hospital	0	3	5	4	1	2	3	4	4	4	5	5	5	5	5	5	3	3
Royal Victoria Regional Health Centre	5	6	6	9	10	10	9	10	10	12	13	11	11	12	12	12	12	12
St. Michael's Hospital	4	2	2	3	2	2	2	1	1	1	1	2	1	1	1	1	1	2
Southlake Regional Health Centre	3	9	8	8	7	6	6	6	6	8	7	9	9	9	9	9	9	9
Thunder Bay Regional Health Sciences Centre	8	5	5	4	3	0	0	3	3	2	3	4	5	4	4	5	5	4
Trillium Health Partners - Credit Valley Hospital	9	4	4	3	6	0	0	1	4	6	6	6	7	7	6	6	6	6
William Osler Health System	0	1	2	2	2	1	1	1	3	2	2	1	2	2	2	2	2	2
The Ottawa Hospital Cancer Centre	56	41	36	34	15	10	27	29	35	37	43	44	43	39	37	38	38	38
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	21	33	33	22	21	21	21	20	21	21	23	24	21	20	20	18	19
R.S. McLaughlin Durham Regional Cancer Centre	13	3	3	2	2	0	2	1	1	3	3	4	3	6	8	8	8	8



Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Newfoundland and Quebec

Network Site	Pre-3CTN Baseline	Y5 Total	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10		
							Q1	% of Baseline	% of Target
Eastern Regional Health Authority	15	15	16	5	10	17	2	13%	7%
Atlantic Total	15	57	36	5	10	17	2	13%	7%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	71	155	90	156	127	27	31%	17%
CHU de Québec – Université Laval, adults	180	99	309	372	456	198	26	14%	8%
Quebec Total	267	170	464	462	612	325	53	20%	11%
<b>Eastern Region Total</b>	<b>282</b>	<b>227</b>	<b>500</b>	<b>467</b>	<b>622</b>	<b>342</b>	<b>55</b>	<b>14%</b>	<b>7%</b>

## Number of active recruiting 3CTN Portfolio Trials – Newfoundland and Quebec

Network Site	Pre-3CTN Baseline	Y6 (2019-20)				Y7 (2020-21)				Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
Eastern Regional Health Authority	6	8	9	10	9	0	6	7	7	9	8	8	6	5	5	6	5	5
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	18	15	24	17	17	18	17	25	29	28	27	21	21	22	22	22	29
CHU de Québec – Université Laval, adults	39	26	26	25	30	27	30	30	23	31	34	31	30	31	30	29	28	32

Patients recruited to 3CTN Portfolio trials, FY2023/24 (Y10) – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y5 Total	Y6 Total	Y7 Total	Y8 Total	Y9 Total	Y10	
							Q1	% of Baseline
BC Children's Hospital	34	-	-	30	24	19	3	9%
CancerCare Manitoba - Pediatrics	18	4	7	12	6	9	1	6%
Centre hospitalier universitaire de Sainte-Justine	42	38	38	51	54	21	8	19%
Children's Hospital - London Health Sciences Centre	12	-	-	5	5	14	1	8%
Children's Hospital of Eastern Ontario	20	-	-	14	16	16	8	40%
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	17	22	21	29	26	18	4	24%
IWK Health Centre	20	-	-	6	11	9	4	20%
Janeway Children's Health and Rehabilitation Centre	4	0	0	5	2	5	0	0%
Jim Pattison Children's Hospital	6	-	-	7	3	4	1	17%
McMaster Children's Hospital - Hamilton Health Sciences Centre	14	-	-	16	24	16	1	7%
Montreal Children's Hospital	24	8	10	16	20	13	0	0%
Stollery Children's Hospital	11	-	-	20	23	11	3	27%
The Hospital for Sick Children	91	-	-	26	73	43	2	2%
<b>Pediatric Total</b>	<b>313</b>	<b>72</b>	<b>76</b>	<b>256</b>	<b>301</b>	<b>198</b>	<b>36</b>	<b>12%</b>


## Number of active recruiting 3CTN Portfolio Trials – Pediatric Cancer Centres

Network Site	Pre-3CTN Baseline	Y6 (2019-20)				Y7 (2020-21)				Y8 (2021-22)				Y9 (2022-23)				Y10 (2022-23)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
BC Children’s Hospital	15	-	-	-	-	13	15	15	17	17	17	17	17	18	19	19	19	20
CancerCare Manitoba - Pediatrics	19	10	9	8	9	9	11	11	13	14	16	16	20	20	20	21	21	22
Centre hospitalier universitaire de Sainte-Justine	9	17	18	18	17	17	18	19	22	22	27	29	27	29	24	22	24	29
Children’s Hospital - London Health Sciences Centre	5	-	-	-	-	14	14	15	18	16	16	14	18	17	16	16	16	17
Children’s Hospital of Eastern Ontario	8	-	-	-	-	8	11	12	17	16	14	16	16	17	17	17	22	17
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	11	17	15	13	11	15	15	15	20	21	20	22	23	19	24	23	22	24
IWK Health Centre	9	-	-	-	-	19	20	22	23	20	19	21	23	25	25	26	26	30
Janeway Children's Health and Rehabilitation Centre	5	5	9	6	6	7	8	8	10	10	13	10	9	10	10	10	10	11
Jim Pattison Children’s Hospital	7	-	-	-	-	8	8	8	8	8	7	7	8	8	8	8	8	8
McMaster Children's Hospital - Hamilton Health Sciences Centre	8	-	-	-	-	12	13	14	17	17	20	20	24	25	25	25	25	25
Montreal Children’s Hospital	5	12	16	16	13	16	17	15	22	22	24	25	26	27	30	30	27	28
Stollery Children’s Hospital	3	-	-	-	-	9	11	13	13	14	13	12	13	15	15	15	16	17
The Hospital for Sick Children	13	-	-	-	-	16	17	17	23	24	30	27	28	28	27	27	27	29

## Section B: 3CTN Portfolio Metrics

### Active Recruiting Portfolio Trials by Disease Site and Phase

**Objective:** To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



## Overview of Portfolio Applications – Process Efficiency

**Objective:** To improve Portfolio application processing time.

### Portfolio Approval Process Timeline<sup>1</sup>

Calendar Year	Number of Applications Received	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2017	45	47	22	6
2018	46	44	18	5
2019	45	45	42	3
2020	41	41	27	0
2021	59	63	29	1
2022	36	33	3	0
2023	35	35	10	0

### Facilitated Peer Review (FPR) Process

Calendar Year	Number of FPR Requests	# FPR Completed <sup>2</sup>	Average FPR Time (days) <sup>3</sup>	Median FPR Time (days) <sup>3</sup>
2017	4	5	79	74
2018	10	7	84	77
2019	16	17	112	86
2020	7	6	137	134
2021	9	13	112	108
2022	3	1	44	44
2023	5	5	57	47

<sup>1</sup> From Portfolio application receipt date to date of approval decision for period beginning Jan 13, 2015.

<sup>2</sup> Counts are based on the completed reviews in that calendar year. E.g., for an application submitted for review in 2019 but completed in 2020, the FPR will be counted for 2020.

<sup>3</sup> FPR process begins on the date the applicant agrees to initiate the FPR process and ends on the date when the final reviewer package is submitted to 3CTN (data based on completed FPRs).

**Link:** [Portfolio Applications Report](#)

## Trials Added to the 3CTN Portfolio in Y10Q1 (April 1 – June 30, 2023)

Trial short title	Trial phase	Disease site	Complexity rating	Trial link
(COG) AOST2032	Phase III	Bone	High	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05691478">NCT05691478</a>
AOST2031	Phase III	Bone	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05235165">NCT05235165</a>
(CONNECT) CONNECT1905	Phase II	Brain/CNS	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05233397">NCT05233397</a>
(CONNECT) CONNECT2108	Phase II	Brain/CNS	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05286788">NCT05286788</a>
(OHRI) REaCT-OGF	Phase IV	Breast	Low/2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05753618">NCT05753618</a>
(OHRI) REaCT-TEMPO	Phase IV	Breast	Low/2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05754528">NCT05754528</a>
(CCTG) CRC.10 / NRG-GI008	Phase II/III	Gastrointestinal	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05174169">NCT05174169</a>
(CCTG) NE.1	Phase II	Gastrointestinal	High	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05773274">NCT05773274</a>
(CHUQ) CHLOE pancreas	Phase I	Gastrointestinal	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04862260">NCT04862260</a>
(CHUQ) BicaBCa	Phase II	Genito-Urinary	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05327647">NCT05327647</a>
(UHN) TOPCOP3	Pilot/Feasibility	Genito-Urinary	Low	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05582772">NCT05582772</a>
NRG - HN009	Phase II/III	Head and neck	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05050162">NCT05050162</a>
(COG) AHOD2131	Phase III	Hematology	High	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05675410">NCT05675410</a>
(CCTG) IND.242	Phase II	Lung	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05714891">NCT05714891</a>
NRG - LU008	Phase III	Lung	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05624996">NCT05624996</a>
(CCTG) IND.243	Phase II	Other	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05605509">NCT05605509</a>
(LHRI) ARREST-2	Phase II/III	Other	Standard	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05508464">NCT05508464</a>

Link: [3CTN's Portfolio Trial Listing](#)